Natural history of children and adults with phenylketonuria in the NBS-PKU Connect registry

被引:17
|
作者
Kenneson, Aileen [1 ]
Singh, Rani H. [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA
[2] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
关键词
Phenylketonuria; Registry; Natural history; Barriers; Psychological disorders; Inherited metabolic disorder; BONE-MINERAL DENSITY; PHENYLPYRUVIC OLIGOPHRENIA; COGNITIVE OUTCOMES; MENTAL-HEALTH; PHENYLALANINE; MANAGEMENT; SYMPTOMS; HYPERPHENYLALANINEMIA; ASSOCIATIONS; ADOLESCENTS;
D O I
10.1016/j.ymgme.2021.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Phenylalanine hydroxylase deficiency, or phenylketonuria (PKU), is a rare autosomal recessive metabolic disorder. Early diagnosis via newborn screening (NBS) and initiation of treatment prevent the development of cognitive impairment and other co-morbidities. The purpose of this study is to describe the natural history of PKU in the United States, including prevalence of co-morbidities and predictors of outcomes. Methods: We analyzed data from a self-report survey in the NBS-PKU Connect online registry. We describe the participants' nutrition management strategies, barriers to management, outcomes of bone disorders, skin, and psychological co-morbidities, and the use of special education or other special services. Predictors of outcomes were identified and assessed, including the impact of sex, age, age at diagnosis, blood phenylalanine concentration, use of sapropterin, use of medical food, adherence to prescribed diet, use of low protein modified foods, whether they had ever been off-diet, and use of tyrosine supplementation. Results: The 219 respondents included individuals with PKU or hyperphenylalanemia (n = 78), or their caregivers (n = 141). Most (84.3%) started treatment before the age of two weeks. About one-third indicated that they had been off-diet at some point in their lives, and 81.4% reported that they currently adhered to their prescribed diet, with adherence to prescribed diet decreasing with age. Blood phenylalanine concentration was under the recommended threshold of 360 mu mol/L for 68.5% of participants. One-quarter of respondents reported psychological co-morbidities, with anxiety and ADD/ADHD being the most common. The incidence of psychological co-morbidities increased with age and with ever having been off diet. Special education or other special services were more likely to be reported by individuals who were diagnosed after one week of age. Skin disorders such as acne and eczema were more common in females than males, and a minority of participants reported bone disorders. Conclusions: Despite recommendations to maintain blood phenylalanine concentrations in the therapeutic range throughout life, it is not uncommon for adults with PKU to discontinue dietary management of their disorder. Early diagnosis was associated with reduced need for special education or other special services, and continuous treatment was associated with decreased psychological co-morbidities. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:243 / 249
页数:7
相关论文
共 45 条
  • [41] Incidence, Natural History and Outcomes of Transient and Persistent Antiphospholipid Antibodies in Children and Young Adults with Provoked Venous Thromboembolism: Analysis of the Kids-DOTT Trial
    Betensky, Marisol
    Anh Thy Nguyen
    Tarango, Cristina
    Verma, Anupam R.
    Bhat, Rukhmi
    Kucine, Nicole
    Nakar, Charles
    Woods, Gary
    Hamblin, Frances L.
    Amankwah, Ernest
    Goldenberg, Neil A.
    BLOOD, 2019, 134
  • [42] NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol
    Wedekind, Mary Frances
    Reilly, Karlyne M.
    Rivero, Jaydira Del
    Lockridge, Robin
    Allen, Taryn
    Raygada, Margarita
    Bernstein, Donna
    Thomas, Barbara J.
    Vivelo, Christina
    Levine, Jason
    Shonkoev, Nurlan
    Aldape, Kenneth
    Glod, John
    Sandler, Abby B.
    Widemann, Brigitte C.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (09)
  • [43] Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study
    Bouman, Karlijn
    Groothuis, Jan T.
    Doorduin, Jonne
    van Alfen, Nens
    ten Cate, Floris E. A. Udink
    van den Heuvel, Frederik M. A.
    Nijveldt, Robin
    van Tilburg, Willem C. M.
    Buckens, Stan C. F. M.
    Dittrich, Anne T. M.
    Draaisma, Jos M. T.
    Janssen, Mirian C. H.
    Kamsteeg, Erik-Jan
    van Kleef, Esmee S. B.
    Koene, Saskia
    Smeitink, Jan A. M.
    Kusters, Benno
    van Tienen, Florence H. J.
    Smeets, Hubert J. M.
    van Engelen, Baziel G. M.
    Erasmus, Corrie E.
    Voermans, Nicol C.
    BMC NEUROLOGY, 2021, 21 (01)
  • [44] Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study
    Karlijn Bouman
    Jan T. Groothuis
    Jonne Doorduin
    Nens van Alfen
    Floris E. A. Udink ten Cate
    Frederik M. A. van den Heuvel
    Robin Nijveldt
    Willem C. M. van Tilburg
    Stan C. F. M. Buckens
    Anne T. M. Dittrich
    Jos M. T. Draaisma
    Mirian C. H. Janssen
    Erik-Jan Kamsteeg
    Esmee S. B. van Kleef
    Saskia Koene
    Jan A. M. Smeitink
    Benno Küsters
    Florence H. J. van Tienen
    Hubert J. M. Smeets
    Baziel G. M. van Engelen
    Corrie E. Erasmus
    Nicol C. Voermans
    BMC Neurology, 21
  • [45] British OsteoNEcrosis Study (BONES) protocol: a prospective cohort study to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma
    Amin, Nadia
    Kinsey, Sally
    Feltbower, Richard
    Kraft, Jeannette
    Whitehead, Elizabeth
    Velangi, Mark
    James, Beki
    BMJ OPEN, 2019, 9 (05):